Esperion to Hold Conference Call to Provide Update On Findings From Study of ETC-216 ANN ARBOR, Michigan, November 4 /PRNewswire/ -- Call Scheduled for Tuesday, November 4, 2003 at 4:30 P.M. Will Detail Findings Related to Study of HDL Therapy in Treatment of Atherosclerosis Esperion Therapeutics, Inc. will hold a conference call to provide detailed findings related to the Company's Phase 2 clinical trial for ETC-216 for the treatment of atherosclerosis. The call is scheduled for Tuesday, November 4, 2003 at 4:30 PM and will be led by Roger S. Newton, Ph.D., President and CEO of Esperion. In initial study results presented in June 2003, the Company announced that ETC-216 demonstrated statistically significant reduction in percent atherosclerotic plaque volume among acute coronary syndrome patients. The Company as well as the study's principal investigator, Steven E. Nissen, M.D., F.A.C.C., medical director of the Cleveland Clinic Cardiovascular Coordinating Centre, continue to confirm the positive results of the study, which showed for the first time that ETC-216 is able to reverse the course of atherosclerotic disease in acute coronary syndrome patients at the end of six weeks. The full data from the study have not been released and remain under embargo until 4:00 p.m. on Tuesday, November 4. Esperion continues to honour the publication embargo and will not comment on rumours or assumptions related to the full data set until after the embargo has been lifted in accordance with standard accepted practices related to publication of data in a peer-reviewed setting. What: Esperion Conference Call on ETC-216 Study Findings When: Tuesday, November 4, 2003 at 4:30 p.m. (ET) Via Telephone: From U.S. and Canada, dial (800) 901-5226 From other locations, dial +1 (617) 786-4513 All callers should give the conference ID "Esperion" when prompted Via Internet: Visit http://www.esperion.com, click on the Investor Relations link, and then click on the Calendar link shortly before 4:30 p.m. (ET) A replay of the Esperion conference call will be available beginning at 8:00 p.m. (ET) on November 4, 2003 until 11:59 p.m. (ET) on November 11, 2003. To access the replay from the U.S. and Canada, dial (888) 286-8010 and enter passcode number 92056812. From all other locations, dial +1 (617) 801-6888 and enter passcode number 92056812. To access the replay via the Internet, visit http://www.esperion.com, click on the Investor Relations link, and then click on the Audio/Visual Archives link. Esperion Therapeutics Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular disease. Esperion intends to commercialise a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function. HDL is the primary facilitator of the RLT pathway by which excess cholesterol and other lipids are removed from arteries and other tissues and are transported to the liver for elimination from the body. Esperion's goal is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has four product candidates in clinical development. Esperion is listed on the Nasdaq National Market under the symbol "ESPR." For more information, visit http://www.esperion.com. Safe Harbor Statement The information contained in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "require," "intend," "assume" and similar expressions. Forward-looking statements speak only as of the date of this press release, reflect management's current expectations, estimations and projections and involve certain factors, such as risks and uncertainties, that may cause actual results, performance or achievements to be far different from those suggested by the Company's forward-looking statements. These factors include, but are not limited to, risks associated with: the Company's ability to successfully execute its business strategies, including entering into strategic partnerships or other transactions; the progress and cost of development of the Company's product candidates; the extent and timing of market acceptance of new products developed by the Company or its competitors; the Company's dependence on third parties to conduct clinical trials for the Company's product candidates; the extent and timing of regulatory approval, as desired or required, for the Company's product candidates; the Company's dependence on licensing arrangements and strategic relationships with third parties; clinical trials; manufacturing; the Company's dependence on patents and proprietary rights; litigation, proceedings, investigations and other disruptions of management's time resulting from the acquisition of the Company's common stock by various persons associated with Scott Sacane; the procurement, maintenance, enforcement and defence of the Company's patents and proprietary rights; competitive conditions in the industry; business cycles affecting the markets in which any of the Company's future products may be sold; extraordinary events and transactions; seeking and consummating business acquisitions, including the diversion of management's attention to the assimilation of the operations and personnel of any acquired business; the timing and extent of the Company's financing needs and the Company's access to funding, including through the equity market, particularly in light of the impact on the market value of the Company's common stock of matters outside of the Company's control, such as trading activities by third parties; fluctuations in foreign exchange rates; and economic conditions generally or in various geographic areas. Because all of the foregoing factors are difficult to forecast, you should not place undue reliance on any forward-looking statement. More detailed information about some of these and other risk factors is set forth in the Company's filings with the Securities and Exchange Commission. The Company does not intend to update any of these factors or to publicly announce the results of any revisions to any of these forward-looking statements other than as required under the federal securities laws. Company Amy Cannon Contact: Manager, Corporate Communications Esperion Therapeutics, Inc. +1 (734) 222-1801 acannon@esperion.com Media Jim Wetmore Contact: Berry & Company Public Relations +1 (212) 253-8881 jwetmore@berrypr.com /CONTACT: Amy Cannon, Manager, Corporate Communications of Esperion Therapeutics, Inc., +1-734-222-1801, acannon@esperion.com; or Jim Wetmore of Berry & Company Public, +1-212-253-8881, jwetmore@berrypr.com, for Esperion Therapeutics, Inc./ /Web site: http://www.esperion.com / (ESPR)

Copyright